ADD-How does the FDA approval of NGS to test for MRD in multiple myeloma affect patients?

In this weeks video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma next-generation sequencing (NGS) and next-generation flow (NGF).

The BOTTOM LINE: The FDA approval of the NGS test for MRD is excellent news, but this testing is still not ready for use in day-to-day clinical practice.